arrow
M

Matteo Sepulcri

Veneto Institute of Oncology IOV-IRCCS
H指数:13
被引数:502

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysis

新辅助化疗免疫疗法治疗可切除非小细胞肺癌的手术结果:一项系统评价和荟萃分析

2026-04-160
PRE
Radiomic approach to support multidisciplinary tumor board decision-making in locally advanced non-small cell lung cancer

基于放射组学方法支持局部晚期非小细胞肺癌的多学科肿瘤委员会决策制定

2025-12-190
OAAI
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials

在可切除非小细胞肺癌患者中使用佐剂、新辅助和围手术期免疫治疗为基础的治疗方案的损耗情况。前瞻性试验的荟萃分析

2025-09-220
PREAI
Oligometastatic Mesothelioma Treated with Ablative Radiotherapy (OMAR): A Multicenter Study

寡转移性间皮瘤经消融放疗治疗(OMAR):一项多中心研究

2025-08-270
OA
Surgery for Pancoast Tumors in Multimodality Setting: Analysis of Outcomes and Risk Factors

多模式治疗环境下Pancoast肿瘤的手术治疗:结局与危险因素分析

2025-04-170
OA
The expanding role of next-generation imaging in prostate cancer management: a cross-sectional survey exploring the clinical practice of uro-oncologists in North-Eastern Italy; on behalf of GUONE (Gruppo Uro-Oncologico del Nord-Est)

下一代成像在前列腺癌管理中不断扩展的作用:一项探索意大利东北部泌尿肿瘤学家临床实践的横断面调查;代表GUONE(Gruppo Uro-Oncologico del Nord-Est)

2025-03-120
OA
Adjuvant modern radiotherapy in resected pN2 NSCLC patients: results from a multicentre retrospective analysis on acute and late toxicity on behalf of AIRO thoracic oncology study group: the RAC-TAC study
2024-08-310
OAAI
Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study

177lu前列腺特异性膜抗原配体治疗转移性去势抵抗性前列腺癌的真实世界结果和预测生物标志物: 欧洲泌尿外科协会年轻学术泌尿科医师前列腺癌工作组多机构观察性研究

2024-06-013
OA
Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort
2024-03-012
OAAI
European Association of Urology Biochemical Recurrence Risk Classification as a Decision Tool for Salvage Radiotherapy-A Multicenter Study
2024-02-0112
PRE
Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis

局部晚期PDL1阴性NSCLC患者放化疗后PD-L1表达的再测定: 回顾性多中心分析

2024-01-314
OAAI